 |
 |
|
|
|
|
 |
|
|
|
|
| Floyd Romesberg, Ph.D. - Principal Scientific Founder | ||
| Dr. Floyd Romesberg is Assistant Professor of Chemistry at The Scripps Research Institute. Dr. Romesberg is an expert on DNA replication, repair, and mutation. Dr. Romesberg's work examining the role of gene products in the active introduction of mutations is the basis of the Achaogen technology platform. He is the recipient of multiple academic awards, including the NSF Career Award (2004), the Susan B. Komen Breast Cancer Foundation Award (2003), the Dreyfus Teacher-Scholar Award (2003), the Baxter Foundation Fellow Award (2002), and the Mac Nevin Award (1987). Dr. Romesberg received his Ph.D. in Chemistry from Cornell University. | ||
| J. Kevin Judice, Ph.D. - Chief Executive Officer | ||
| Dr. Judice was most recently head of the medicinal chemistry group at Genentech, where he provided strategic direction to the growing small molecule effort within the company. Prior to Genentech, he served as Vice President of Medicinal Chemistry at Theravance, Inc. (formerly Advanced Medicine, Inc.), a role in which he had line responsibility for more than 90 of the company's roughly 180 scientists. During his early years at Theravance, Dr. Judice served as project team leader for the group which discovered telavancin (TD-6424), a rapidly bactericidal agent which is currently in Phase 2 human clinical trials. Subsequent to that, Dr. Judice oversaw all of the medicinal chemistry efforts during a period in which two more compounds were advanced to clinical trials — including an asthma agent which was successful in Phase 2 clinical trials and a compound (currently in Phase 1) to treat overactive bladder disorders. An additional five compounds have been nominated as development candidates by Theravance since its founding in 1997. Dr. Judice received his bachelor's degree at Texas A&M, his Ph.D. at UCLA, and was awarded an NIH postdoctoral fellowship at Berkeley. | ||
| Nathaniel David, Ph.D. - Principal Entrepreneurial Founder | ||
| Nathaniel David was co-founder of Syrrx (www.syrrx.com), a next-generation rational drug discovery company. As one of the earliest employees of Cell Genesys, Inc., Dr. David was one of the genetic engineers responsible for developing the Xenomouse, a transgenic animal now marketed by Abgenix, Inc. Dr. David received his A.B. in Biology from Harvard College (1990) and his Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley (1998). In 2002, Dr. David was named one of the top 100 innovators in the world under 35 by the MIT Technology Review. |